Parecoxib

A potent and selective COX-2 inhibitor; a water-soluble prodrug of valdecoxib.Pain Approved (In Vitro) :Parecoxib (0-200 μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells.Parecoxib (200 μM; 24-48 hours) results in a decreasee migratory ability of U343 cells than PBS-treated group. (In Vivo) :Parecoxib (intraperitoneal injection; 2.5, 5.0 or 10 mg/kg; once a day; 21 days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10 mg/kg shows higher levels of percentage of time spent in the open arms.